1. Market Research
  2. > Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2013

Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 131 pages

Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2013” provides data on the Dainippon Sumitomo Pharma Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Dainippon Sumitomo Pharma Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Dainippon Sumitomo Pharma Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Dainippon Sumitomo Pharma Co., Ltd. - Brief Dainippon Sumitomo Pharma Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Dainippon Sumitomo Pharma Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Dainippon Sumitomo Pharma Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Dainippon Sumitomo Pharma Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Dainippon Sumitomo Pharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Dainippon Sumitomo Pharma Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Dainippon Sumitomo Pharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Dainippon Sumitomo Pharma Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Dainippon Sumitomo Pharma Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

Dainippon Sumitomo Pharma Co., Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 5
Dainippon Sumitomo Pharma Co., Ltd. Snapshot 6
Dainippon Sumitomo Pharma Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Dainippon Sumitomo Pharma Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Pipeline Products - Out-Licensed Products 16
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products Glance 18
Dainippon Sumitomo Pharma Co., Ltd. - Late Stage Pipeline Products 18
Dainippon Sumitomo Pharma Co., Ltd. - Clinical Stage Pipeline Products 20
Dainippon Sumitomo Pharma Co., Ltd. - Early Stage Pipeline Products 22
Dainippon Sumitomo Pharma Co., Ltd. - Unknown Stage Pipeline Products 24
Dainippon Sumitomo Pharma Co., Ltd. - Drug Profiles 25
amrubicin hydrochloride 25
blonanserin 27
droxidopa 29
lurasidone hydrochloride 32
metformin hydrochloride 34
ranirestat 35
vatiquinone 36
afacifenacin 38
AZD-8848 39
DSP-6952 41
glycopyrrolate 42
obeticholic acid 44
SEP-225289 47
zonisamide 48
WT-4869 50
ceftaroline fosamil 52
DSP-2230 54
WT-2725 55
Benzoxazolone Derivatives 56
Drugs Targeting Ras Signaling Pathway 57
DSP-0011 58
DSR-6434 59
EPI-589 60
NEP-28 61
Phosphodiesterase 4 Inhibitors 62
Selective M1/M4 Muscarinic Acetylcholine Receptor Agonist 63
SM-276001 64
SM-295291 65
SM-324405 66
SM-369926 67
AIM 68
Calcium/Calmodulin-Dependent Protein Kinase II Inhibitors 69
Compound-14 70
Dipeptidyl Peptidase IV Inhibitor 71
GCGR Antagonist-1 72
Microsomal Prostaglandin E Synthase-1 Inhibitors 73
Piperidine Derivatives 74
RPE Cells for Ophthalmic Disorders 75
limaprost 76
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Analysis 77
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Therapeutic Class 77
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Target 81
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Route of Administration 86
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Molecule Type 88
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Mechanism of Action 89
Dainippon Sumitomo Pharma Co., Ltd. - Recent Pipeline Updates 93
Dainippon Sumitomo Pharma Co., Ltd. - Dormant Projects 114
Dainippon Sumitomo Pharma Co., Ltd. - Discontinued Pipeline Products 116
Discontinued Pipeline Product Profiles 116
Dainippon Sumitomo Pharma Co., Ltd. - Company Statement 120
Dainippon Sumitomo Pharma Co., Ltd. - Locations And Subsidiaries 121
Head Office 121
Other Locations and Subsidiaries 121
Dainippon Sumitomo Pharma Co., Ltd. - Key Manufacturing Facilities 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 128
Disclaimer 128



List of Tables

Dainippon Sumitomo Pharma Co., Ltd., Key Information 9
Dainippon Sumitomo Pharma Co., Ltd., Key Facts 9
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Indication, 2013 12
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Stage of Development, 2013 15
Dainippon Sumitomo Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2013 16
Dainippon Sumitomo Pharma Co., Ltd. - Partnered Products in Pipeline, 2013 17
Dainippon Sumitomo Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2013 18
Dainippon Sumitomo Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2013 19
Dainippon Sumitomo Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2013 20
Dainippon Sumitomo Pharma Co., Ltd. - Pre-Registration, 2013 21
Dainippon Sumitomo Pharma Co., Ltd. - Phase III, 2013 22
Dainippon Sumitomo Pharma Co., Ltd. - Phase II, 2013 23
Dainippon Sumitomo Pharma Co., Ltd. - Phase I, 2013 24
Dainippon Sumitomo Pharma Co., Ltd. - Preclinical, 2013 25
Dainippon Sumitomo Pharma Co., Ltd. - Discovery, 2013 26
Dainippon Sumitomo Pharma Co., Ltd. - Unknown, 2013 27
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Therapeutic Class, 2013 81
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Target, 2013 85
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Route of Administration, 2013 90
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Molecule Type, 2013 91
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2013 93
Dainippon Sumitomo Pharma Co., Ltd. - Recent Pipeline Updates, 2013 96
Dainippon Sumitomo Pharma Co., Ltd. - Dormant Developmental Projects,2013 117
Dainippon Sumitomo Pharma Co., Ltd. - Discontinued Pipeline Products, 2013 119
Dainippon Sumitomo Pharma Co., Ltd., Other Locations 124
Dainippon Sumitomo Pharma Co., Ltd., Subsidiaries 127
Dainippon Sumitomo Pharma Co., Ltd., Key Manufacturing Facilities 129



List of Figures

Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2013 11
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Stage of Development, 2013 15
Dainippon Sumitomo Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2013 16
Dainippon Sumitomo Pharma Co., Ltd. - Partnered Products in Pipeline, 2013 17
Dainippon Sumitomo Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2013 19
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Top 10 Therapeutic Class, 2013 80
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Top 10 Target, 2013 84
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2013 89
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2013 91
Dainippon Sumitomo Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2013 92



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.